The Effect of Evolving Strategies in the Surgical Management of Organ-Confined Prostate Cancer: Comparison of Data from 2005 to 2014 in a Multicenter Setting
The objective of this study was to evaluate changes of patient characteristics and surgical techniques in radical prostatectomy in Germany within the last decade.MethodsData from 44 German prostate cancer centers were included in the study. Patients ’ characteristics (age, initial PSA value), surgical techniques (open vs. minimally invasive approaches), perioperative parameters (operating time, rate of nerve-sparing (NS) radical prostatectomies (RPs), hospitalization time, catheter indwelling time, surgical margin status, number of dissected lymph nodes (LN)), and pathological findings (tumor stage, Gleason score) ...
Source: Advances in Therapy - January 4, 2017 Category: Drugs & Pharmacology Source Type: research

Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study
ConclusionThis study of mavoglurant in OCD was terminated because of the lack of efficacy at interim analysis. The study did not support the use of an antagonist of mGluR5 receptors for OCD treatment.Trial RegistrationThe study was registered with ClinicalTrials.gov: NCT01813019.FundingThis study was sponsored by Novartis Pharma AG, Basel, Switzerland. (Source: Advances in Therapy)
Source: Advances in Therapy - January 2, 2017 Category: Drugs & Pharmacology Source Type: research

Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer
AbstractIntroductionAndrogen deprivation therapy (ADT) is a mainstay of treatment against advanced prostate cancer (PC). As a treatment goal, suppression of plasma testosterone levels to
Source: Advances in Therapy - December 27, 2016 Category: Drugs & Pharmacology Source Type: research

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
AbstractObinutuzumab (GA101) is a novel, type II, glycoengineered, humanized anti-CD20 monoclonal antibody that has been developed to address the need for new therapeutics with improved efficacy in patients with lymphocytic leukemia and lymphoma of B-cell origin. Obinutuzumab has a distinct mode of action relative to type I anti-CD20 antibodies, such as rituximab, working primarily by inducing direct cell death and antibody-dependent cell-mediated cytotoxicity. Obinutuzumab is under investigation in a wide-ranging program of clinical trials in patients with B-cell malignancies. Efficacy as monotherapy has been reported in ...
Source: Advances in Therapy - December 21, 2016 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China
ConclusionsThe analysis found that apixaban was not cost-effective and that rivaroxaban was inferior to enoxaparin. This finding indicates that compared with enoxaparin, the use of apixaban for VTE prophylaxis after THR does not represent a good value for the cost at the acceptable threshold in China; in addition, the cost of rivaroxaban was higher with lower QALYs. (Source: Advances in Therapy)
Source: Advances in Therapy - December 20, 2016 Category: Drugs & Pharmacology Source Type: research

Caregiver Preference and Treatment Compliance in Patients with Mild-to-Moderate Alzheimer ’s Disease in South Korea: RECAP Study Results
AbstractIntroductionThe aim of this study was to assess caregiver preference and treatment compliance with oral and transdermal medications in a “real-world” setting in patients with mild-to-moderate Alzheimer’s disease (AD) in South Korea.MethodsReal-world evaluation of compliance and preference in Alzheimer ’s disease treatment (RECAP) was a 24-week, multicenter, prospective, non-interventional study in patients with AD treated with oral or transdermal therapy. Here, we report data from patients living in South Korea. Eligible patients were grouped into one of two treatment cohorts: oral (donepezi...
Source: Advances in Therapy - December 20, 2016 Category: Drugs & Pharmacology Source Type: research

Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma
AbstractThe approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound heali...
Source: Advances in Therapy - December 20, 2016 Category: Drugs & Pharmacology Source Type: research

Patient Satisfaction with Collection of Patient-Reported Outcome Measures in Routine Care
ConclusionsSystematic collection of PROMs via an electronic questionnaire appears to be well accepted by patients. A minority of patients did not feel the questionnaire content applied to their appointment or that the system was a beneficial feature of the clinical practice. The provider can significantly improve the patient ’s perception of PROM collection and the patient–physician encounter by reviewing the questionnaire results with the patient. (Source: Advances in Therapy)
Source: Advances in Therapy - December 20, 2016 Category: Drugs & Pharmacology Source Type: research

Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison
ConclusionThe relative treatment effect of GM-CSF, dacarbazine, and gp100 has been reliably estimated by adjusting for differences in baseline prognostic factors. Results suggest that OS with GM-CSF is at least as good as with dacarbazine and greater than with gp100. Given the role of these agents as controls in phase  3 trials of new immunotherapies and targeted agents, these results can be used to contextualize the efficacy of newer therapies.FundingAmgen Inc. (Source: Advances in Therapy)
Source: Advances in Therapy - December 20, 2016 Category: Drugs & Pharmacology Source Type: research

Chronic Obstructive Pulmonary Disease Individualized Therapy: Tailored Approach to Symptom Management
AbstractChronic obstructive pulmonary disease (COPD) is associated with high morbidity and mortality. COPD is typified by persistent, progressive airflow limitation and a range of respiratory and systemic symptoms such as breathlessness, coughing, wheezing, depression, anxiety, general fatigue, and sleeping difficulties. Despite receiving treatment for COPD, many patients suffer from regular symptoms that affect their daily lives and lead to increased morbidity. These symptoms vary in severity, frequency, and type, and can occur at any time throughout the 24-h day, with over half of patients with COPD experiencing symptoms...
Source: Advances in Therapy - December 15, 2016 Category: Drugs & Pharmacology Source Type: research

A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids
AbstractCardiovascular (CV) disease remains the leading cause of preventable death in the US. Hyperlipidemia is a major modifiable risk factor for CV disease, and after numerous clinical trials have demonstrated that reductions in low-density lipoprotein (LDL) cholesterol with statin therapy can prevent major adverse CV events, statins have emerged as the drug of choice to lower LDL cholesterol and reduce CV risk. However, some statin-treated patients remain at high residual risk of CV events despite achieving low LDL cholesterol levels, especially if their triglyceride (TG) levels are elevated or their high-density lipopr...
Source: Advances in Therapy - December 15, 2016 Category: Drugs & Pharmacology Source Type: research

Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
ConclusionCanagliflozin induced transient sodium excretion and did not induce water intake at Day 1; hence, natriuresis rather than glucose-induced osmotic diuresis may be a major factor involved in the canagliflozin-induced transient increase in urine output. In addition, canagliflozin decreased plasma ANP and NT-proBNP levels and increased plasma renin activity, which may be a compensatory mechanism for sodium retention, leading to subsequent urine output recovery.Clinical trial registrationUMIN000019462.FundingMitsubishi Tanabe Pharma Corporation. (Source: Advances in Therapy)
Source: Advances in Therapy - December 15, 2016 Category: Drugs & Pharmacology Source Type: research

Hospitalization Costs for Patients Undergoing Orthopedic Surgery Treated With Intravenous Acetaminophen (IV-APAP) Plus Other IV Analgesics or IV Opioid Monotherapy for Postoperative Pain
AbstractIntroductionTo assess the impact on hospitalization costs of multimodal analgesia (MMA), including intravenous acetaminophen (IV-APAP), versus IV opioid monotherapy for postoperative pain management in patients undergoing orthopedic surgery.MethodsUtilizing the Truven Health MarketScan® Hospital Drug Database (HDD), patients undergoing total knee arthroplasty (TKA), total hip arthroplasty (THA), or surgical repair of hip fracture between 1/1/2011 and 8/31/2014 were separated into postoperative pain management groups: MMA with IV-APAP plus other IV analgesics (IV-APAP group) or an IV opioid monotherapy group. Al...
Source: Advances in Therapy - December 10, 2016 Category: Drugs & Pharmacology Source Type: research

Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor
AbstractApproximately 1 in 3 –4 patients presenting with an ischemic stroke will also have atrial fibrillation (AF), and AF-related strokes can be effectively prevented using oral anticoagulant therapy (OAC), either with well-controlled vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs). In a ddition, OAC use (both VKAs and NOACs) is associated with a 26% reduction in all-cause mortality (VKAs) or an additional 10% mortality reduction with NOACs relative to VKAs. The decision to use OAC in individual AF patient is based on the estimated balance of the benefit from ischemic stroke red...
Source: Advances in Therapy - December 8, 2016 Category: Drugs & Pharmacology Source Type: research

Healthcare Costs Among Patients with Heart Failure: A Comparison of Costs between Matched Decedent and Survivor Cohorts
AbstractIntroductionPrior research suggests increased costs during the final months of life, yet little is known about healthcare cost differences between patients with heart failure (HF) who die or survive.MethodsA retrospective claims study from a large US health plan [commercial and Medicare Advantage with Part D (MAPD)] was conducted. Patients were ≥18 years old with two non-inpatient or one inpatient claim(s) with HF diagnosis code(s). The earliest HF claim date during 1 January 2010–31 December 2011 was the index date. Cohort assignment was based on evidence of death within 1 year (decedents) or su...
Source: Advances in Therapy - December 8, 2016 Category: Drugs & Pharmacology Source Type: research

Efficacy of a Novel Prefilled, Single-Use, Needle-Free Device (Zeneo ® ) in Achieving Intramuscular Agent Delivery: An Observational Study
ConclusionUse of the Zeneo® auto-injector achieves delivery depth that ensures intramuscular delivery in both men and women, regardless of BMI. Consistent with other reported data, STMD is greater in women.FundingCrossject. (Source: Advances in Therapy)
Source: Advances in Therapy - December 7, 2016 Category: Drugs & Pharmacology Source Type: research

Opioid-Induced Bowel Dysfunction in Patients Undergoing Spine Surgery: Comparison of Oxycodone and Oxycodone-Naloxone Treatment
ConclusionIn patients presented for back surgery, the prevalence of constipation was significantly higher than that in the community. In opioid-na ïve subjects, oxycodone-naloxone was beneficial concerning constipation; but this was not distinguishable in subjects with chronic opioid use. The analgesic efficacy of oxycodone and oxycodone-naloxone was similar.Trial registration: European Clinical Trials Database (EudraCT no. 2012-001816-42) and ClinicalTrials.gov database (Identifier: NCT02573922). (Source: Advances in Therapy)
Source: Advances in Therapy - December 5, 2016 Category: Drugs & Pharmacology Source Type: research

24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy
AbstractIntroductionThe aim of the present study was to evaluate the 24-h efficacy, tolerability, and ocular surface health with preservative-free (PF) tafluprost and a PF triple drug regimen comprising tafluprost and dorzolamide/timolol fixed combination (DTFC) in open-angle glaucoma patients who were insufficiently controlled with preserved branded or generic latanoprost monotherapy and who exhibited signs or symptoms of ocular surface disease (OSD).MethodsProspective, observer-masked, crossover, comparison. Eligible consecutive open-angle glaucoma patients were randomized to either PF tafluprost or the triple PF regimen...
Source: Advances in Therapy - December 2, 2016 Category: Drugs & Pharmacology Source Type: research

Sirukumab: A Potential Treatment for Mood Disorders?
AbstractConvergent evidence indicates that abnormalities in the innate immune system may be pertinent to the pathogenesis, phenomenology, and possible treatment of several mental disorders. In keeping with this view, the targeting of interleukin-6 with the human monoclonal antibody sirukumab may represent a possible treatment and disease modification approach, for adults with brain-based disorders (e.g., major depressive disorder). A PubMed/Medline database search was performed using the following search terms: sirukumab; anti-IL-6; IL-6; major depressive disorder; inflammation. A systematic review was conducted of both pr...
Source: Advances in Therapy - December 2, 2016 Category: Drugs & Pharmacology Source Type: research

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
ConclusionIsavuconazole is a cost-effective option for the treatment of IA among hospitalized patients.FundingAstellas Pharma Global Development, Inc. (Source: Advances in Therapy)
Source: Advances in Therapy - December 2, 2016 Category: Drugs & Pharmacology Source Type: research

Randomized Controlled Trial of Hyalobarrier ® Versus No Hyalobarrier ® on the Ovulatory Status of Women with Periovarian Adhesions: A Pilot Study
ConclusionThe use of Hyalobarrier® post salpingo-ovariolysis did not influence follicular development as inferred from the results of the day 21 progesterone and folliculogram on day 10 –12 3-month postsurgery.Trial RegistrationISRCTN number, ISRCTN1833588.FundingNordic Pharma. (Source: Advances in Therapy)
Source: Advances in Therapy - November 29, 2016 Category: Drugs & Pharmacology Source Type: research

A Randomized, Clinical Trial to Evaluate Efficacy and Tolerability of Trypsin:Chymotrypsin as Compared to Serratiopeptidase and Trypsin:Bromelain:Rutoside in Wound Management
AbstractIntroductionSystemic enzyme therapy can play an important role in maintaining normal inflammatory processes within the body and thereby helps support and speed up healing. In the course of the anti-inflammatory action, enzymes degrade damaged cells and necrotic material and, through the inactivation of mediators and toxic products, they restrict the edema and pain.MethodThe study conducted at Grant Medical College, Mumbai, India was a clinical trial comparing the efficacy and tolerability of three oral enzyme treatment groups —oral tablets containing trypsin:chymotrypsin (TC) (Chymoral Forte®), serratiope...
Source: Advances in Therapy - November 26, 2016 Category: Drugs & Pharmacology Source Type: research

True Incidence of Gleason 6 Pathology in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
ConclusionThe development of mCRPC in patients with true Gleason 6 pathology is very rare and could not be confirmed in our series. This finding may have important implications in future treatment planning. (Source: Advances in Therapy)
Source: Advances in Therapy - November 26, 2016 Category: Drugs & Pharmacology Source Type: research

Estimated Budget Impact of Adopting the Affordable Care Act ’s Required Smoking Cessation Coverage on United States Healthcare Payers
ConclusionThe projected PMPM impact of covering two quit attempts with access to all seven cessation medications at no patient cost share remains low. Results of this study reinforce that the impact of adopting the ACA requirements for smoking cessation coverage will have a limited near-term impact on health plan ’s budgets.FundingPfizer Inc. (Source: Advances in Therapy)
Source: Advances in Therapy - November 25, 2016 Category: Drugs & Pharmacology Source Type: research

Erratum to: Clinical and Biological Principles of Cold Atmospheric Plasma Application in Skin Cancer
(Source: Advances in Therapy)
Source: Advances in Therapy - November 25, 2016 Category: Drugs & Pharmacology Source Type: research

Erratum to: nab -Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
(Source: Advances in Therapy)
Source: Advances in Therapy - November 24, 2016 Category: Drugs & Pharmacology Source Type: research

Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS)
ConclusionsThese preliminary data underline that the standard algorithm used is a valid tool for a proper diagnosis of BTP in cancer patients. Moreover, rapid relief of pain is crucial for patients ’ satisfaction. The final IOPS-MS data are necessary to understand relationships between BTP characteristics and other clinical variables in oncologic patients.FundingMolteni Farmaceutici, Italy. (Source: Advances in Therapy)
Source: Advances in Therapy - November 21, 2016 Category: Drugs & Pharmacology Source Type: research

Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data
ConclusionsThese findings suggest that blinatumomab provides substantial overall survival benefit to patients with (R/R) Ph( −) B-precursor ALL compared with salvage chemotherapy.FundingAmgen.Trial RegistrationClinicalTrials.gov identifier NCT01466179 and NCT02003612. (Source: Advances in Therapy)
Source: Advances in Therapy - November 21, 2016 Category: Drugs & Pharmacology Source Type: research

Association of Performance Status and Pain in Metastatic Bone Pain Management in the Spanish Clinical Setting
AbstractIntroductionBone metastasis is the most common cause of cancer-related pain, and metastatic bone pain (MBP) is not only severe but also progressive in many patients. The aim of this study was to investigate the association between pain management and performance status in patients with metastatic bone cancer in the Spanish clinical setting.MethodsA 3-month follow-up prospective, epidemiologic, multicenter study was conducted in 579 patients to assess the evolution of their performance, the impact of pain control on sleep and functionality, and the degree of pain control according to analgesic treatment.ResultsIn pa...
Source: Advances in Therapy - November 21, 2016 Category: Drugs & Pharmacology Source Type: research

Unproven Therapies for Diabetes and Their Implications
AbstractDiabetes is a chronic disease and is one of the leading causes of morbidity and mortality worldwide. Being an ancient disease, many individuals follow complementary and alternative medicinal (CAM) therapies for either the cure or prevention of the disease. The popularity of these practices among the general public is in no way a testimony to their safety and efficacy. Due to the possibility of undesirable interactions with conventional medicines, it is imperative that patients are asked about CAM use during patient assessment. Patient- and physician-targeted awareness programs on various aspects of CAM use must be ...
Source: Advances in Therapy - November 18, 2016 Category: Drugs & Pharmacology Source Type: research

Examining the Impact of Rehospitalization on Healthcare Cost of Myocardial Infarction Patients in Beijing: A Retrospective Observational Study
AbstractIntroductionTo examine the impact of rehospitalization on the healthcare expenditure of myocardial infarction (MI) patients in Beijing.MethodsRetrospective data of MI patients were retrieved from the Beijing Medical Insurance Database, an administrative database of social medical reimbursement activities for the urban population in Beijing, China. Ten percent of patients diagnosed with MI from January 1 to December 31, 2012 were randomly selected and their first hospitalization was considered as the index event. Their hospital utilization after the index event was extracted till September 30, 2013. Rehospitalizatio...
Source: Advances in Therapy - November 18, 2016 Category: Drugs & Pharmacology Source Type: research

Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study
The objective of this study was to determine beliefs about systemic medications in patients with IMIDs and to explore the association of those beliefs and other factors with adherence.MethodsThis was a multi-country, cross-sectional, self-administered survey study. Included were adults diagnosed with one of six IMIDs receiving conventional systemic medications and/or tumor necrosis factor inhibitors (TNFi). Patients ’ necessity beliefs/concerns towards and adherence to treatments were assessed by the Beliefs about Medicines Questionnaire and four-item Morisky Medication Adherence Scale. Correlation of patients’...
Source: Advances in Therapy - November 16, 2016 Category: Drugs & Pharmacology Source Type: research

Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview
This article reviews the efficacy and safety of canagliflozin in combination with metformin based on data from t he canagliflozin phase 3 clinical program. As initial combination therapy in drug-naïve patients or as dual therapy with metformin or triple therapy in combination with metformin and other AHAs, canagliflozin 100 and 300 mg improved glycemic control and provided reductions in body weight and systo lic blood pressure that were sustained for up to 104 weeks. Canagliflozin was generally well tolerated across studies in combination with metformin. An increased incidence of adverse events (AEs) related...
Source: Advances in Therapy - November 16, 2016 Category: Drugs & Pharmacology Source Type: research

Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials
ConclusionOverall, incretin therapy does not appear to increase risk for MACE in the short term. (Source: Advances in Therapy)
Source: Advances in Therapy - November 14, 2016 Category: Drugs & Pharmacology Source Type: research

Estimating the Effect of Intravenous Acetaminophen for Postoperative Pain Management on Length of Stay and Inpatient Hospital Costs
ConclusionsThis investigation indicates that reducing opioid use and including IV APAP for postoperative pain management has the potential to decrease LOS, opioid-related complication rates, and costs from a hospital perspective.FundingMallinckrodt Pharmaceuticals. (Source: Advances in Therapy)
Source: Advances in Therapy - November 9, 2016 Category: Drugs & Pharmacology Source Type: research

Potential Impact of Biologically Derived Hyaluronic Acid on Quality of Life in Patients with Knee Osteoarthritis in the United States
ConclusionsThis study demonstrates that more widely used, biologically derived, high molecular weight IA-HAs, such as Euflexxa, have the potential to save a substantial number of QALYs among the US population with symptomatic knee osteoarthritis.Funding: Ferring Pharmaceuticals Inc. (Source: Advances in Therapy)
Source: Advances in Therapy - November 3, 2016 Category: Drugs & Pharmacology Source Type: research

Preferences Regarding Shared Decision-Making in Japanese Inflammatory Bowel Disease Patients
ConclusionThe present study found that the majority of IBD patients in Japan wanted to have a role in their treatment plan. The results indicate that the patient ’s preference in regard to SDM was driven by their perception of the severity or progression of their disease.FundingJanssen Pharmaceuticals. (Source: Advances in Therapy)
Source: Advances in Therapy - November 2, 2016 Category: Drugs & Pharmacology Source Type: research

Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review
AbstractThe Hepatic CHEMOSAT® Delivery System is an innovative medical device for the treatment of patients with unresectable primary liver tumors or unresectable hepatic metastases from solid organ malignancies. This system is used to perform chemosaturation percutaneous hepatic perfusion (CS-PHP), a procedure in which a high dose of the chemotherapeutic agent melphalan is delivered directly to the liver while limiting systemic exposure. In a clinical trial program, CS-PHP with melphalan significantly improved hepatic progression-free survival in patients with unresectable hepatic metastases from ocular or cutaneous m...
Source: Advances in Therapy - October 31, 2016 Category: Drugs & Pharmacology Source Type: research

Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
ConclusionsThe results of this survey highlight a significant need for evidence-based education about biosimilars for physicians across specialties. Five major knowledge gaps were identified: defining biologics, biosimilars, and biosimilarity; understanding the approval process and the use of “totality of evidence” to evaluate biosimilars; understanding that the safety and immunogenicity of a biosimilar are comparable to the originator biologic; understanding the rationale for extrapolation of indications; and defining interchangeability and the related rules regarding pharmacy-level substitution.Funding: Biosi...
Source: Advances in Therapy - October 31, 2016 Category: Drugs & Pharmacology Source Type: research

Self-Administration of Medicines and Dietary Supplements Among Female Amateur Runners: A Cross-Sectional Analysis
ConclusionsOur study showed that self-administration of products among female runners seems to be a widespread behavior, where the intensity of the sports practice and the network of runners seem to influence the decision to resort to this behavior. (Source: Advances in Therapy)
Source: Advances in Therapy - October 31, 2016 Category: Drugs & Pharmacology Source Type: research

Assessing Short-term Deterioration in Maintenance-na ïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials
AbstractIntroductionDual bronchodilator therapy is reserved as a second-line treatment in patients with chronic obstructive pulmonary disease (COPD) and provides benefits in lung function and health status versus monotherapy. The aim of this study was to determine whether early initiation of a dual bronchodilator versus monotherapy reduced the risk of deterioration in COPD.MethodsThis post hoc pooled analysis investigated the efficacy and safety of umeclidinium/vilanterol (UMEC/VI) 62.5/25  mcg/day compared with tiotropium (TIO) 18 mcg/day in a maintenance-naïve (MN) subgroup of patients relative to the inte...
Source: Advances in Therapy - October 28, 2016 Category: Drugs & Pharmacology Source Type: research

Response to: Important Considerations When Determining the Cost-effectiveness of Viscosupplements in the Treatment of Knee Osteoarthritis
(Source: Advances in Therapy)
Source: Advances in Therapy - October 24, 2016 Category: Drugs & Pharmacology Source Type: research

Important Considerations When Determining the Cost-effectiveness of Viscosupplements in the Treatment of Knee Osteoarthritis: Letter to the Editor regarding Rosen, J., Sancheti, P., Fierlinger, A. et al. Adv Ther (2016) 33: 998. doi:10.1007/s12325-016-0331-8
(Source: Advances in Therapy)
Source: Advances in Therapy - October 24, 2016 Category: Drugs & Pharmacology Source Type: research

Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study
AbstractIntroductionThe present study was aimed at comparing the antihypertensive efficacy, tolerability, and side effects profile of nebivolol/hydrochlorothiazide (NH) vs irbesartan/hydrochlorothiazide (IH) combination in elderly patients with isolated systolic hypertension (ISH).Methods124 ISH patients aged 69.1  ± 5.1 years (mean ± SD) were enrolled by 13 general practitioners in Netherlands and Belgium and randomized in a double-blind fashion to receive either NH (5/12.5 mg day,n = 62) or IH (150/12.5 mg day,n = 62) for a 12-week period. The prim...
Source: Advances in Therapy - October 22, 2016 Category: Drugs & Pharmacology Source Type: research

Points to Consider in the Foundation of Multidisciplinary Units for Psoriatic Arthritis: A Delphi Study and a Systematic Review of the Literature
ConclusionsThis consensus offers some points to consider, including premises and recommendations, for the development of specialized Units in the management of PsA based on expert opinion. We trust these guidelines may facilitate their implementation in the future.FundingPfizer. (Source: Advances in Therapy)
Source: Advances in Therapy - October 18, 2016 Category: Drugs & Pharmacology Source Type: research

Reasons for and Against Use of Non-absorbable, Synthetic Mesh During Pelvic Organ Prolapse Repair, According to the Prolapsed Compartment
AbstractAwareness and reporting of mesh-related complications of pelvic organ prolapse repairs have increased in recent years. As a result, deciding whether to use a mesh or not has become a difficult task for urogynecologists. Our aim was to summarize reasons for and against the use of mesh in prolapse repair based on a review of relevant literature. Scopus and PubMed databases were searched for papers reporting on the efficacy and safety of native tissue versus non-absorbable, synthetic mesh prolapse repairs. Randomized controlled trials, systematic reviews, and meta-analyses were included. Evidence is presented for each...
Source: Advances in Therapy - October 18, 2016 Category: Drugs & Pharmacology Source Type: research

α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?
AbstractAvailable α1-blockers (ABs) have different profiles of receptor selectivity. Silodosin exhibits the highest selectivity for the α1A adrenergic receptor. This pharmacological feature couples with a singular urodynamic and clinical profile. The magnitude of bladder outlet obstruction improvement in patients receiving silodosin is higher if compared to other ABs. From a clinical point of view, current evidence suggests an advantage in favor of silodosin in terms of nocturia improvement and cardiovascular safety. The incidence of ejaculatory dysfunction with silodosin is higher compared to other Abs. (Sourc...
Source: Advances in Therapy - October 17, 2016 Category: Drugs & Pharmacology Source Type: research

Lack of a Pharmacokinetic Interaction Between SYM-1219 Granules Containing 2 Grams of Secnidazole and a Combined Oral Contraceptive in a Phase 1, Randomized, Open-Label Study in Healthy Female Volunteers
ConclusionSYM-1219 is a valuable single-dose treatment option for women with BV that will not interfere with combined oral contraceptive methods.FundingSymbiomix Therapeutics. (Source: Advances in Therapy)
Source: Advances in Therapy - October 15, 2016 Category: Drugs & Pharmacology Source Type: research

Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study
ConclusionsBiosimilar filgrastim was effective and well-tolerated in both the primary and secondary prophylactic setting in patients undergoing chemotherapy for solid tumors and hematological malignancies.Trial RegistrationClinicalTrials.gov identifier, NCT01627990.FundingHospira Inc, A Pfizer Company, Lake Forest, IL, USA. (Source: Advances in Therapy)
Source: Advances in Therapy - October 14, 2016 Category: Drugs & Pharmacology Source Type: research

Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design
This study registered athttp://www.chictr.org.cn (registration number: ChiCTR-OOC-16007902).FundingSanofi (China) Investment Co., Ltd. (Source: Advances in Therapy)
Source: Advances in Therapy - October 14, 2016 Category: Drugs & Pharmacology Source Type: research